Related Experiment Video
Updated: Jul 8, 2026
04:07
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in
Emily H Chaplin1, David J Reeves1,2
1Franciscan Health Indianapolis, IN, USA.
The Annals of Pharmacotherapy
|July 7, 2026
Summary
Prior use of poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer patients may increase the risk of neutropenia during subsequent chemotherapy. This highlights the need for careful monitoring and supportive care in patients previously treated with PARPi maintenance therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Poly (ADP-ribose) polymerase inhibitors (PARPis) are a standard maintenance therapy for ovarian cancer.
- PARPis are known to cause myelosuppression.
- Limited data exists on the impact of prior PARPi exposure on subsequent chemotherapy tolerance.
Purpose of the Study:
- To investigate the association between prior PARPi maintenance therapy and myelosuppression during second-line chemotherapy for ovarian cancer.
Main Methods:
- Retrospective, single-center cohort study.
- Adult women with ovarian cancer receiving second-line chemotherapy (Jan 2017-Jun 2024).
- Comparison of patients with and without prior PARPi maintenance therapy; primary outcome: neutropenia.
Main Results:
- Prior PARPi maintenance was associated with a significantly higher frequency of neutropenia (91% vs 52%, OR=9.35).
- PARPi-exposed patients had lower median nadir absolute neutrophil count (ANC) and increased use of G-CSF prophylaxis.
- Multivariable analysis confirmed the association between prior PARPi use and neutropenia.
Conclusions:
- Prior PARPi maintenance therapy may increase the risk of neutropenia during subsequent chemotherapy for ovarian cancer.
- Findings suggest a need for heightened monitoring and supportive care, including G-CSF use, in PARPi-exposed patients.
- Further validation in larger studies is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...